366 related articles for article (PubMed ID: 31677820)
1. Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.
Lorusso D; Ferrandina G; Colombo N; Pignata S; Pietragalla A; Sonetto C; Pisano C; Lapresa MT; Savarese A; Tagliaferri P; Lombardi D; Cinieri S; Breda E; Sabatucci I; Sabbatini R; Conte C; Cecere SC; Maltese G; Scambia G
Gynecol Oncol; 2019 Dec; 155(3):406-412. PubMed ID: 31677820
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA).
Simpkins F; Drake R; Escobar PF; Nutter B; Rasool N; Rose PG
Gynecol Oncol; 2015 Feb; 136(2):240-5. PubMed ID: 25485782
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.
Aghajanian C; Filiaci V; Dizon DS; Carlson JW; Powell MA; Secord AA; Tewari KS; Bender DP; O'Malley DM; Stuckey A; Gao J; Dao F; Soslow RA; Lankes HA; Moore K; Levine DA
Gynecol Oncol; 2018 Aug; 150(2):274-281. PubMed ID: 29804638
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
Komiyama S; Kato K; Inokuchi Y; Takano H; Matsumoto T; Hongo A; Asai-Sato M; Arakawa A; Kamiura S; Tabata T; Takeshima N; Sugiyama T
Int J Clin Oncol; 2019 Jan; 24(1):103-114. PubMed ID: 30030657
[TBL] [Abstract][Full Text] [Related]
5. A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer.
Engel-Riedel W; Lowe J; Mattson P; Richard Trout J; Huhn RD; Gargano M; Patchen ML; Walsh R; Trinh MM; Dupuis M; Schneller F
J Immunother Cancer; 2018 Feb; 6(1):16. PubMed ID: 29486797
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma.
Rose PG; Ali S; Moslemi-Kebria M; Simpkins F
Int J Gynecol Cancer; 2017 Mar; 27(3):452-458. PubMed ID: 28187088
[TBL] [Abstract][Full Text] [Related]
7. Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.
Fader AN; Roque DM; Siegel E; Buza N; Hui P; Abdelghany O; Chambers S; Secord AA; Havrilesky L; O'Malley DM; Backes FJ; Nevadunsky N; Edraki B; Pikaart D; Lowery W; ElSahwi K; Celano P; Bellone S; Azodi M; Litkouhi B; Ratner E; Silasi DA; Schwartz PE; Santin AD
Clin Cancer Res; 2020 Aug; 26(15):3928-3935. PubMed ID: 32601075
[TBL] [Abstract][Full Text] [Related]
8. Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer.
Redondo A; Colombo N; McCormack M; Dreosti L; Nogueira-Rodrigues A; Scambia G; Lorusso D; Joly F; Schenker M; Ruff P; Estevez-Diz M; Irahara N; Donica M; Gonzalez-Martín A
Gynecol Oncol; 2020 Oct; 159(1):142-149. PubMed ID: 32763109
[TBL] [Abstract][Full Text] [Related]
9. Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S; Scambia G; Schettino C; Arenare L; Pisano C; Lombardi D; De Giorgi U; Andreetta C; Cinieri S; De Angelis C; Priolo D; Casanova C; Rosati M; Greco F; Zafarana E; Schiavetto I; Mammoliti S; Cecere SC; Salutari V; Scalone S; Farolfi A; Di Napoli M; Lorusso D; Gargiulo P; Califano D; Russo D; Spina A; De Cecio R; Chiodini P; Perrone F;
Lancet Oncol; 2023 Mar; 24(3):286-296. PubMed ID: 37052965
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.
Scudder SA; Liu PY; Wilczynski SP; Smith HO; Jiang C; Hallum AV; Smith GB; Hannigan EV; Markman M; Alberts DS;
Gynecol Oncol; 2005 Mar; 96(3):610-5. PubMed ID: 15721401
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis.
Ishikawa M; Shibata T; Iwata T; Nishio S; Takada T; Suzuki S; Horie K; Kudaka W; Kagabu M; Tanikawa M; Kitagawa R; Takekuma M; Kobayashi H; Yaegashi N;
Gynecol Oncol; 2021 Aug; 162(2):292-298. PubMed ID: 34016453
[TBL] [Abstract][Full Text] [Related]
12. Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group.
Saloustros E; Nikolaou M; Kalbakis K; Polyzos A; Christofillakis C; Kentepozidis N; Pistamaltzian N; Kourousis C; Vamvakas L; Georgoulias V; Mavroudis D
Clin Breast Cancer; 2018 Feb; 18(1):88-94. PubMed ID: 29153775
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†.
Dingemans AM; Groen HJ; Herder GJ; Stigt JA; Smit EF; Bahce I; Burgers JA; van den Borne BE; Biesma B; Vincent A; van der Noort V; Aerts JG;
Ann Oncol; 2015 Nov; 26(11):2286-93. PubMed ID: 26347109
[TBL] [Abstract][Full Text] [Related]
14. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Walker JL; Brady MF; Wenzel L; Fleming GF; Huang HQ; DiSilvestro PA; Fujiwara K; Alberts DS; Zheng W; Tewari KS; Cohn DE; Powell MA; Van Le L; Davidson SA; Gray HJ; Rose PG; Aghajanian C; Myers T; Alvarez Secord A; Rubin SC; Mannel RS
J Clin Oncol; 2019 Jun; 37(16):1380-1390. PubMed ID: 31002578
[TBL] [Abstract][Full Text] [Related]
15. An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
Spigel DR; Luft A; Depenbrock H; Ramlau R; Khalil M; Kim JH; Mayo C; Chao GY; Obasaju C; Natale R
Clin Lung Cancer; 2017 Sep; 18(5):480-488. PubMed ID: 28365238
[TBL] [Abstract][Full Text] [Related]
16. An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
Gore M; Hackshaw A; Brady WE; Penson RT; Zaino R; McCluggage WG; Ganesan R; Wilkinson N; Perren T; Montes A; Summers J; Lord R; Dark G; Rustin G; Mackean M; Reed N; Kehoe S; Frumovitz M; Christensen H; Feeney A; Ledermann J; Gershenson DM
Gynecol Oncol; 2019 Jun; 153(3):541-548. PubMed ID: 31005287
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer.
Suzuki K; Nagao S; Shibutani T; Yamamoto K; Jimi T; Yano H; Kitai M; Shiozaki T; Matsuoka K; Yamaguchi S
Gynecol Oncol; 2019 Sep; 154(3):554-557. PubMed ID: 31285082
[TBL] [Abstract][Full Text] [Related]
18. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.
Leslie KK; Filiaci VL; Mallen AR; Thiel KW; Devor EJ; Moxley K; Richardson D; Mutch D; Secord AA; Tewari KS; McDonald ME; Mathews C; Cosgrove C; Dewdney S; Casablanca Y; Jackson A; Rose PG; Zhou X; McHale M; Lankes H; Levine DA; Aghajanian C
Gynecol Oncol; 2021 Apr; 161(1):113-121. PubMed ID: 33541735
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer.
Pectasides D; Xiros N; Papaxoinis G; Pectasides E; Sykiotis C; Koumarianou A; Psyrri A; Gaglia A; Kassanos D; Gouveris P; Panayiotidis J; Fountzilas G; Economopoulos T
Gynecol Oncol; 2008 May; 109(2):250-4. PubMed ID: 18299146
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer.
Zhang L; Zhou Q
Eur J Pharmacol; 2018 Oct; 837():64-71. PubMed ID: 30059681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]